Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla, Dr Reddy’s, Viatris And Teva Named In US Revlimid Antitrust Suit

ANDA Sponsors ‘Restrained Competition And Maintained Shared Monopoly’

Executive Summary

Months after the first generic versions of Bristol-Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) debuted in the US, indirect purchasers of the treatment for multiple myeloma have accused the originator and a raft of settling ANDA sponsors that their deals were anticompetitive.

You may also be interested in...



Zydus Sees Revlimid Generic Revenues Beyond Q4 As It Waits For Antitrust Suit To Play Out

Zydus, along with Bristol Myers Squibb and generics companies like Mylan, Cipla and Dr. Reddy’s, has been named in an antitrust suit involving BMS’ blockbuster drug Revlimid. For now, it expects revenues from the generic to stretch beyond Q4 FY’23. Meanwhile, a recent acquisition of Watson, which made APIs for the Teva group, should shore up declining API revenues

Two Of Aurobindo’s Europe Biosimilar Filings Stuck

Even as two biosimilar filings in Europe are stuck due to a lack of inspection staff and a biosimilar could be approved in the UK without a Phase III trial, Aurobindo has licensed novel drug Ryzneuta from Yifan Pharma. Meanwhile, a $650m-$700m revenue forecast for the specialty business has been pushed back as both overall revenues and profits declined during Q2.

Two Of Aurobindo’s Europe Biosimilar Filings Stuck, Licenses Ryzneuta From Yifan Pharma

Even as two biosimilar filings in Europe are stuck due to a lack of inspection staff and a biosimilar could be approved in the UK without a Phase III trial, Aurobindo has licensed novel drug Ryzneuta from Yifan Pharma. Meanwhile, a $650-700m revenue forecast for the specialty business has been pushed back as both overall revenues and profits declined during Q2.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel